Patent application number | Description | Published |
20080287498 | Optically active isomers of ketotifen and therapeutically active metabolites thereof - Racemic norketotifen, racemic 10-hydroxy-ketotifen, racemic 10-hydroxy-nor-ketotifen and optically active isomers of ketotifen, norketotifen, 10-hydroxy-ketotifen and 10-hydroxy-norketotifen were found to have antiallergic and anti-inflammatory effects while being devoid of the severe dose-limiting sedative side effects of Ketotifen. | 11-20-2008 |
20090004235 | Methods of Accelerating Muscle Growth, Decreasing Fat Deposits and Improving Feed Efficiency in Livestock Animals - A method of promoting or improving the feed efficiency and the muscle to fat ratio in animals by administering to the animals a therapeutically effective amount of a pure or substantially pure RR-isomer of ractopamine is disclosed. Also disclosed are animal feed preparations and compositions and pharmaceutical preparations capable of increasing lean meat deposition in an animal or decreasing body fat, or promoting or improving the growth of an animal or improving the feed efficiency of an animal. Feed preparation, compositions and pharmaceutical preparations including therapeutically effective amounts of a pure or substantially pure RR-isomer of ractopamine are disclosed | 01-01-2009 |
20090054338 | Synergisms between repartitioning and immunomodulating compounds - Combination therapies of adrenergic beta-receptor agonists and beta-glucans are described. | 02-26-2009 |
20090137628 | Formulations of Indanylamines and the Use Thereof as Local Anesthetics and as Medication for Chronic Pain - Dermal and mucosal formulations of 2-[2-(N-phenyl-N-2-indanyl)aminoethyl]piperidine, characterized by rapid dermal and mucosal absorption and long duration of therapeutic activity are provided. Also provided are solutions of 2-[2-(N-phenyl-N-2-indanyl)aminoethyl]piperidine for injection, characterized by short onset time and long duration of activity. Formulations containing both 2-[2-(N-phenyl-N-2-indanyl)aminoethyl]piperidine and capsaicin are also provided. | 05-28-2009 |
20090143480 | Use of RR/SR-ractopamine - A method of promoting or improving the feed efficiency and the muscle-to-fat ratio in animals by administering to the animals a therapeutically effective amount of a mixture of RR-ractopamine and SR-ractopamine is disclosed. Manufacturing methods for making RR/SR-ractopamine are presented. | 06-04-2009 |
20100041704 | DERMAL COMPOSITIONS OF SUBSTITUTED AMIDES AND THE USE THEREOF AS MEDICATION FOR PAIN AND PRURITUS - Dermal compositions comprising topical formulations of bupivacaine or ropivacaine, characterized by effective dermal absorption and long duration of dermal anesthetic activity, and intended for use in patients suffering from pruritus and dermal pain, including neuropathic pain, are provided. Compositions containing both bupivacaine and capsaicin are provided. Methods of alleviating pain by the topically administration of these compounds are also provided. | 02-18-2010 |
20100105734 | Treatment xerophthalmia with norketotifen - Methods of using a cycloheptathiophene compound for the treatment of xerophthalmia are described, as are formulations and compositions for such treatment. | 04-29-2010 |
20100130550 | OCULAR FORMULATIONS OF NORKETOTIFEN - Ophthalmic compositions containing norketotifen and methods of making the same and the use thereof are disclosed. The methods also comprise administering to the eyes of a mammal in need thereof topical ophthalmic compositions containing norketotifen. | 05-27-2010 |
20100184865 | Use Of RR/SR-Ractopamine - A method of promoting weight loss in animals or humans by administering thereto a therapeutically effective amount of a mixture of RR-ractopamine and SR-ractopamine is disclosed. | 07-22-2010 |
20110218218 | Formulations Of Indanylamines And The Use Thereof As Local Anesthetics And As Medication For Chronic Pain - Internal-dermal formulations of RS—, S—, or R-2-[2-(N-phenyl-N-2-indanyl)aminoethyl]piperidine causing intradermal accumulation of said piperidine and intended for the treatment of neuropathic pain are provided, as well as a method of inducing the relief of pain using the compounds. | 09-08-2011 |
20110294897 | Treating Xerophthalmia With Compounds Increasing Meibomian Gland Secretion - Methods for the treatment of patients suffering from dry eyes, by using adrenergic beta-receptor agonists, particularly salbutamol and in particular the optically pure or substantially pure R-enantiomer thereof. The embodiments disclosed herein include methods of increasing the Meibomian lipid secretion and thereby reducing or eliminating xerophthalmia symptoms by the administration of formulations containing therapeutically effective amounts of an adrenergic beta-receptor agonist to said patients. In particular, certain embodiments disclosed herein concern compositions that contain R-salbutamol as the active beta-receptor stimulating ingredient. In certain embodiments, the formulations are administered to the ocular surface of the eye and/or to the eyelid (the underside of the eyelid and/or the top of the eyelid) of a patient in need thereof. | 12-01-2011 |
20120065271 | METHOD OF ACCELERATING MUSCLE GROWTH, DECREASING FAT DEPOSITS AND IMPROVING FEED EFFICIENCY IN LIVESTOCK ANIMALS - A method of promoting or improving the feed efficiency and the muscle to fat ratio in animals by administering to the animals a therapeutically effective amount of a pure or substantially pure RR-isomer of ractopamine is disclosed. Also disclosed are animal feed preparations and compositions and pharmaceutical preparations capable of increasing lean meat deposition in an animal or decreasing body fat, or promoting or improving the growth of an animal or improving the feed efficiency of an animal. Feed preparation, compositions and pharmaceutical preparations including therapeutically effective amounts of a pure or substantially pure RR-isomer of ractopamine are disclosed | 03-15-2012 |
20130090295 | METHODS OF ACCELERATING MUSCLE GROWTH, DECREASING FAT DEPOSITS AND IMPROVING FEED EFFICIENCY IN LIVESTOCK ANIMALS - A method of promoting or improving the feed efficiency and the muscle to fat ratio in animals by administering to the animals a therapeutically effective amount of a pure or substantially pure RR-isomer of ractopamine is disclosed. Also disclosed are animal feed preparations and compositions and pharmaceutical preparations capable of increasing lean meat deposition in an animal or decreasing body fat, or promoting or improving the growth of an animal or improving the feed efficiency of an animal. Feed preparation, compositions and pharmaceutical preparations including therapeutically effective amounts of a pure or substantially pure RR-isomer of ractopamine are disclosed. | 04-11-2013 |
20140113936 | MEDICINAL TREATMENT OF DERMAL DISEASES IN COMPANION ANIMALS - The methods disclosed herein relate to the treatment of skin infections in dogs, by-administering a therapeutically effective amount of norketotifen. Therapeutic antimicrobial activity of norketotifen against | 04-24-2014 |
20140120121 | MEDICINAL TREATMENT OF ATOPIC INFLAMMATORY DISEASES - The methods disclosed herein relate to the treatment of atopic inflammatory disorders, such as dermal or pulmonary atopic inflammatory disorders, in humans, by administering a therapeutically effective amount of ractopamine. | 05-01-2014 |
20140303091 | OCULAR FORMULATIONS OF NORKETOTIFEN - Ophthalmic compositions containing norketotifen and methods of making the same and the use thereof are disclosed. The methods also comprise administering to the eyes of a mammal in need thereof topical ophthalmic compositions containing norketotifen. | 10-09-2014 |
20150045392 | METHODS OF TREATING PRURITIC CONDITIONS MEDIATED THROUGH HISTAMINE H-4 RECEPTORS - The methods disclosed herein relate to the treatment of histamine H-4—related pruritus, by administering a histamine H-4 receptor inverse agonist that selectively accumulates at the biophases of the disorders, specifically RS-norketotifen or a pharmaceutically acceptable salt thereof. Potentiated antipruritic activity by simultaneous inhibition of histamine H-1 receptors and histamine H-4 receptors are described. | 02-12-2015 |